Clinical Trial Update: Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results for CVT-301 in Parkinson's disease patients with OFF episodes have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CVT-301 (levodopa inhalation powder)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-07-30